[go: up one dir, main page]

DK0491628T3 - Lipopeptides inducing cytotoxic T lymphocytes and their use as vaccines - Google Patents

Lipopeptides inducing cytotoxic T lymphocytes and their use as vaccines

Info

Publication number
DK0491628T3
DK0491628T3 DK91403446T DK91403446T DK0491628T3 DK 0491628 T3 DK0491628 T3 DK 0491628T3 DK 91403446 T DK91403446 T DK 91403446T DK 91403446 T DK91403446 T DK 91403446T DK 0491628 T3 DK0491628 T3 DK 0491628T3
Authority
DK
Denmark
Prior art keywords
hiv
lymphocytes
lipopeptides
vaccines
inducing cytotoxic
Prior art date
Application number
DK91403446T
Other languages
Danish (da)
Inventor
Frederic Martinon
Remy Magne
Hel Na Gras-Masse
Andre Tartar
Christophe Boutillon
Christian Sergheraert
Elisabeth Gomard
Jean-Paul Levy
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9403372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0491628(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK0491628T3 publication Critical patent/DK0491628T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The use of a lipopeptide (I) is claimed for the immunization of humans or animals against pathogens or tumor cells, where (I) contains: (i) a peptide component having 10-40 (preferably 10-20) amino acids; (ii) at least one antigenic determinant which specifically induces cytotoxic T-lymphocytes; and (iii) one or more chains derived from N- epsilon -palmitoyl-L-lysine, coupled to the carboxy functions of the aminoacids. An Independent claim is included for a lipopeptide (I') for immunization against HIV-1 or HIV-2, comprising (I) as above in which component (i) is a fragment of an HIV-1 or HIV-2 protein.
DK91403446T 1990-12-18 1991-12-18 Lipopeptides inducing cytotoxic T lymphocytes and their use as vaccines DK0491628T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9015870A FR2670787B1 (en) 1990-12-18 1990-12-18 LIPOPEPTIDES INDUCING CYTOTOXIC T CELLS AND USE AS VACCINES.

Publications (1)

Publication Number Publication Date
DK0491628T3 true DK0491628T3 (en) 2000-04-10

Family

ID=9403372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91403446T DK0491628T3 (en) 1990-12-18 1991-12-18 Lipopeptides inducing cytotoxic T lymphocytes and their use as vaccines

Country Status (10)

Country Link
EP (3) EP0491628B1 (en)
JP (2) JP3821305B2 (en)
AT (1) ATE185148T1 (en)
CA (1) CA2057828C (en)
DE (1) DE69131662T2 (en)
DK (1) DK0491628T3 (en)
ES (1) ES2137160T3 (en)
FR (1) FR2670787B1 (en)
GR (1) GR3031889T3 (en)
SG (1) SG63621A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547681A2 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a lipopeptide
FR2771640B1 (en) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med MIXED MICELLES OF LIPOPEPTIDES FOR INDUCING AN IMMUNE RESPONSE AND THEIR USES FOR THERAPEUTIC PURPOSES
FR2776926B1 (en) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med LYMPHOCYTARY T CYTOTOXICITY T INDUCING LIPOPEPTIDES CARRYING AT LEAST ONE AUXILIARY T EPITOPE, AND THEIR USES FOR VACCINATION
FR2821556B1 (en) * 2001-03-02 2003-04-25 Aventis Pasteur USE OF LIPOPEPTIDES FOR IMMUNOTHERAPY OF HIV + SUBJECTS
JP2004533421A (en) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Vaccine for modulating between T1 and T2 immune responses
TWI395591B (en) 2004-04-01 2013-05-11 Oncothyreon Inc Mucinous glycoprotein (muc-1) vaccine
PT1896051E (en) 2005-06-28 2015-01-13 Oncothyreon Inc Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
BRPI1009194A2 (en) 2009-03-10 2016-11-01 Baylor Res Inst vaccines targeting antigen presenting cell
CA2754862C (en) 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
ES2622228T3 (en) 2009-03-10 2017-07-06 Baylor Research Institute Antiviral vaccines targeting antigen presenting cells
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
WO2012135132A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416407A (en) * 1981-11-02 1983-11-22 Dennison Manufacturing Company Dispensing of fasteners with a pivoted and disengageable feed mechanism
ZA831547B (en) * 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
EP0203676B1 (en) * 1985-04-19 1992-01-29 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic t cell response protective against a virus
AU626797B2 (en) * 1987-09-08 1992-08-13 Albany Medical College Immunogenic composites capable of selectively inducing antibody production, pharmaceutical compositions employing the same and method of selectively inducing antibody production
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
GB2355009A (en) * 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts

Also Published As

Publication number Publication date
CA2057828A1 (en) 1992-06-19
ES2137160T3 (en) 1999-12-16
EP0491628B1 (en) 1999-09-29
JPH04295498A (en) 1992-10-20
JP3821305B2 (en) 2006-09-13
DE69131662D1 (en) 1999-11-04
EP1065212A2 (en) 2001-01-03
EP0945461A1 (en) 1999-09-29
EP0491628A2 (en) 1992-06-24
ATE185148T1 (en) 1999-10-15
GR3031889T3 (en) 2000-02-29
FR2670787A1 (en) 1992-06-26
SG63621A1 (en) 1999-11-16
JP2004043501A (en) 2004-02-12
EP0491628A3 (en) 1992-07-22
FR2670787B1 (en) 1995-06-23
DE69131662T2 (en) 2000-04-06
CA2057828C (en) 2007-06-12
EP1065212A3 (en) 2001-01-10

Similar Documents

Publication Publication Date Title
DK0491628T3 (en) Lipopeptides inducing cytotoxic T lymphocytes and their use as vaccines
DK532184A (en) ANTIGEN AMINO ACID SEQUENCES
ATE373010T1 (en) GAG ANTIGEN AND ITS USE FOR DETECTING LAV INFECTION, AND IN IMMUNOGENIC COMPOSITIONS
CY1106875T1 (en) NEISSERIA ANTIGONAL PIPES
ATE229978T1 (en) HELICOBACTER PROTEINS AND VACCINES
GB2255093A (en) Hiv-1 core protein fragments
DE68925660D1 (en) HIV peptide fragments
ATE103294T1 (en) PEPTIDE FRAGMENTS OF HIV.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
NO983054D0 (en) Viral recombinant pseudoparticles and use as vaccines and as anti-tumor agents
DK0732339T3 (en) Peptides from the HIV gag protein, preparation and use thereof
DK0426314T3 (en) HIV-related peptides
DK204588D0 (en) HUMAN RHINOVIRUS PEPTIDES, PROCEDURES FOR THEIR PREPARATION AND VACCINES CONTAINING SUCH PEPTIDES
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus